Navigation Links
Alexion Completes Enrollment in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
Date:3/20/2008

CHESHIRE, Conn., March 20 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. (the "Company") (Nasdaq: ALXN) today announced that it has completed enrolling patients in its previously announced AEGIS study, a single registration study to evaluate the safety, efficacy, and pharmacology of Soliris(R) (eculizumab) as a treatment for Japanese patients with paroxysmal nocturnal hemoglobinuria (PNH). The open-label study, which was authorized by Japan's Pharmaceutical and Medical Device Administration (PMDA), over-enrolled a total of 29 patients. The patients will be treated with Soliris at clinical sites throughout Japan for 12 weeks.

PNH is a rare, acquired genetic blood disorder defined by hemolysis, in which patients' red blood cells are destroyed by complement, a component of the body's immune system. The primary efficacy endpoint of the study is reduction of hemolysis from baseline. The study will also measure the effect of Soliris on other clinical manifestations of PNH, including blood transfusion requirements, thromboses (blood clots), and kidney function. Important measures of patients' overall quality of life, including fatigue, will also be assessed.

The inclusion and exclusion criteria for the AEGIS study are similar to those used in the SHEPHERD study, one of Alexion's previous Phase 3 studies of Soliris as a treatment for PNH. SHEPHERD examined the safety and efficacy of eculizumab in a broad and diverse population of patients with PNH, including patients with minimal transfusion requirements and/or evidence of thrombocytopenia. (1) Based on the SHEPHERD study and the companion TRIUMPH Phase 3 study, (2) Soliris was approved in 2007 as the first treatment for patients with PNH by the U.S. Food and Drug Administr
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
2. Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
3. NanoBio Corporation Successfully Completes Phase 2b Study in Herpes Labialis
4. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
5. Isolagen, Inc. Completes Enrollment in Isolagen Therapy(TM) Phase II/III Acne Scar Study
6. NanoBio(R) Corporation Completes $30 Million in Equity Funding by Meeting Key Development Milestones
7. Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA)
8. MonoSol Rx Completes Thin Film Ondansetron Pilot Bioequivalence Study
9. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
10. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
11. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... DUBLIN , January 15, 2014 Shire plc ... waived the Office of Fair Trading (OFT) approval condition to the ... Incorporated (NASDAQ: VPHM).   As a result of the ... Shire expects to complete the tender offer on January 24, 2014 ...
(Date:1/15/2014)... is very pleased to announce the appointment of Mr. ... Mark was promoted from his current role of Chief Operating ... in Massachusetts , Mississippi ... 2012 with 20+ years of broad-based operations, sales, engineering and ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... – Worldwide Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Analysis Insulin Pumps ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
... Anemia test menu expanded through use of advanced LOCI(R) chemiluminescence ... ... Jan. 16 Siemens Healthcare,Diagnostics, today announced that it has launched ... the Dimension Vista(R),1500 Intelligent Lab System, an ultra-integrated chemistry analyzer. These,tests ...
... and Drug Administration (FDA) has accepted for filing the ... XR(TM) (levetiracetam) in the, adjunctive treatment of ... Jan. 16 UCB announced today that the New ... extended-,release tablets in the adjunctive treatment of partial onset ...
Cached Medicine Technology:Siemens Healthcare Diagnostics Launches B12, Folate, and Ferritin Tests on Its Dimension vista Intelligent Lab System 2Siemens Healthcare Diagnostics Launches B12, Folate, and Ferritin Tests on Its Dimension vista Intelligent Lab System 3Keppra XR(TM) Extended-Release Tablets Filed with the FDA 2Keppra XR(TM) Extended-Release Tablets Filed with the FDA 3Keppra XR(TM) Extended-Release Tablets Filed with the FDA 4
(Date:4/17/2014)... Meaningful long-term survival is possible for selected patients ... treated with cytoreductive surgery with Hyperthermic IntraPeritoneal Chemotherapy, ... physicians at Wake Forest Baptist Medical Center. , ... experience with cytoreductive surgery and HIPEC, said lead ... 20 years, worth of patient data shows that ...
(Date:4/17/2014)... Canadians surveyed said they would participate in public health ... genetic conditions, only 80 per cent said they would ... their newborns, genomes.,Most newborns in North America have a ... of life in which a tiny amount of blood ... five to 54 conditions, depending on the state or ...
(Date:4/17/2014)... have called for more research to be carried ... in sub-Saharan Africa. In a paper in ... Stothard, working with colleagues in the department of ... in Cleveland Ohio, University of Cambridge and the ... the joint burden of HIV/AIDS and schistosomiasis of ...
(Date:4/16/2014)... Texas (April 16, 2014) A team that includes scientists ... Health Science Center at San Antonio, Johns Hopkins University and ... helps a common fungus to infect the body. , The ... rashes and oral thrush, and is the most common fungal ...
(Date:4/15/2014)... Handling frozen fish caused nearly half of all ... the injuries on freezer-longliner vessels operating off the coast ... , Many of those injuries and others aboard the ... right interventions, and the research methods used in the ...
Breaking Medicine News(10 mins):Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2Health News:Researcher looks at public perceptions around newborn testing 2Health News:Researcher looks at public perceptions around newborn testing 3Health News:More research called for into HIV and schistosomiasis coinfection in African children 2Health News:Changes in processing, handling could reduce commercial fishing injuries 2
... Diego – Obesity is back in the news with one ... Cancer. People who are obese carry an enhanced risk of ... California, San Diego have unearthed the link between obesity and ... the obese secrete a hormone called leptin, which induces growth ...
... proportions”, a study finding which says that hormone replacement therapy ... of heart disease. , The study published in ... replacement therapy or HRT, taken by women in their 50’s ... attacks and other such conditions. , This finding ...
... a possible herbal cure for urinary track// infection (UTI). ... Center found that the herb called forskalin or ... UTI as well as help antibiotics kill 90 percent of ... and Urologic Diseases Information Clearinghouse (NKUDIC) says urinary tract infections ...
... will soon start an integrated trauma care facility to ... //to patients on way to a hospital from an ... of Physicians of Indian Origin (AAPI), the emergency medical ... fully equipped ambulances within minutes of an accident., ...
... of developing colon cancer, the third most common form of ... body of obese people produce leptin - a hormone that ... a person has, the more leptin will be in their ... Surgery. ,A colon cancer patient suffers from cancerous ...
... US-based ImClone Systems and Bristol-Myers Squibb have announced that ... with platinum-based //chemotherapy have increased survival chances among cancer ... the head and neck (SCCHN). ,Worldwide SCCHN ... head and neck, and approximately two-thirds of all patients ...
Cached Medicine News:Health News:Hormone Replacement Therapy- Not A Fallen Angel 2Health News:Ancient Indian Herb May Prove Cure For Recurrent UTI 2Health News:Integrated Trauma Care Facility in Mumbai 2Health News:Integrated Trauma Care Facility in Mumbai 3Health News:A New Erbitux Combo Shows Promise in treatment 2
SURGISPIKE™ Single Use 5 mm Trocar. , ,Bladed Trocars are devices that contain a metal blade to gain access to the abdominal cavity....
... Surgical Access ...unlike any trocar system you've ... is actually four systems in one ... clinically adaptive to all of your needs., ... bladed or dilating tip styles, OnePort™ can ...
... The complete line of Surgical Access ...unlike ... ,The OnePort™ trocar system is actually four ... versatile, operationally flexible and clinically adaptive to ... options in disposability and bladed or dilating ...
... Pak contains: (1) 15mm obturator, ... (1) 12mm ENDOPATH thoracic trocar ... Pak contains: (1) 15mm obturator, ... ,FPK03 Thoracic Trocar Pak contains: ...
Medicine Products: